Cargando…

CD19-targeting fusion protein combined with PD1 antibody enhances anti-tumor immunity in mouse models

In our previous studies, using a B cell vaccine (scFv-Her2), the targeting of tumor-associated antigen Her2 (human epidermal growth factor receptor-2) to B cells via the anti-CD19 single chain variable fragment (scFv) was shown to augment tumor-specific immunity, which enhanced tumor control in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Zhuangwei, Zhang, Ping, Li, Dandan, Qin, Mengting, Nie, Longzhu, Wang, Xiaoqian, Ai, Li, Feng, Zhaozu, Odhiambo, Woodvine Otieno, Ma, Yunfeng, Ji, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185221/ https://www.ncbi.nlm.nih.gov/pubmed/32363119 http://dx.doi.org/10.1080/2162402X.2020.1747688

Ejemplares similares

Involvement of Blnk and Foxo1 in tumor suppression in BCR-ABL1-transformed pro-B cells
por: Zhang, Ping, et al.
Publicado: (2021)

AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines
por: Jiao, Junna, et al.
Publicado: (2020)

Identification and characterization of a murine model of BCR-ABL1(+) acute B-lymphoblastic leukemia with central nervous system metastasis
por: Yu, Xiaozhuo, et al.
Publicado: (2019)

Aloe-Emodin-Mediated Photodynamic Therapy Attenuates Sepsis-Associated Toxins in Selected Gram-Positive Bacteria In Vitro
por: Otieno, Woodvine, et al.
Publicado: (2021)

RAG enhances BCR‐ABL1‐positive leukemic cell growth through its endonuclease activity in vitro and in vivo
por: Yuan, Meng, et al.
Publicado: (2021)

Probiotic Lactobacillus Species and Their Biosurfactants Eliminate Acinetobacter baumannii Biofilm in Various Manners
por: Al-Shamiri, Mona Mohamed, et al.
Publicado: (2023)

ELEVATED PD-1/CD28 RATIO RATHER THAN PD-1 EXPRESSION IN CD8(+) T CELLS PREDICTS NOSOCOMIAL INFECTION IN SEPSIS PATIENTS: A PROSPECTIVE, OBSERVATIONAL COHORT STUDY
por: Zhong, Wenhong, et al.
Publicado: (2022)

Inflammation accelerates BCR-ABL1(+) B-ALL development through upregulation of AID
por: Zhang, Ping, et al.
Publicado: (2022)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

A mouse pancreatic organoid model to compare PD-L1 blocking antibodies
por: Li, Guangyuan, et al.
Publicado: (2022)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: Implications for the development of severe anemia
por: Odhiambo, Collins O, et al.
Publicado: (2008)

Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: Implications for the development of severe anemia
por: Odhiambo, Collins O, et al.
Publicado: (2010)

Fusion of apoptosis‐related protein Cytochrome c with anti‐HER‐2 single‐chain antibody targets the suppression of HER‐2+ breast cancer
por: Lu, DanDan, et al.
Publicado: (2021)

IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy
por: Li, Song, et al.
Publicado: (2023)

Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors
por: Ishikura, Nobuyuki, et al.
Publicado: (2022)

Immuno-PET Monitoring of CD8(+) T Cell Infiltration Post ICOS Agonist Antibody Treatment Alone and in Combination with PD-1 Blocking Antibody Using a (89)Zr Anti-CD8(+) Mouse Minibody in EMT6 Syngeneic Tumor Mouse
por: Alsaid, Hasan, et al.
Publicado: (2022)

The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis
por: Huang, Guanghong, et al.
Publicado: (2017)

Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells
por: Pandey, Madhu S., et al.
Publicado: (2021)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Combination CD200R/PD-1 blockade in a humanised mouse model
por: Fellermeyer, Martin, et al.
Publicado: (2023)

MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells
por: Zheng, Zhong, et al.
Publicado: (2019)

Leveraging cloud computing for improved health service delivery: Findings from public health facilities in Kisumu County, Western Kenya‐2019
por: Ogwel, Billy, et al.
Publicado: (2021)

PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases
por: Sandker, Gerwin G. W., et al.
Publicado: (2022)

Pediatric patient with a complex Abdominal Wall defect reconstructed with sandwich omental flap. A case report()
por: Otieno, Daniel Odhiambo, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
por: Yang, Yun, et al.
Publicado: (2023)

Peripheral CD8+CD28+ T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
por: Geng, Ruixuan, et al.
Publicado: (2023)

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY
por: Zhang, Huilai, et al.
Publicado: (2023)

Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models
por: Guo, Zhiqiang, et al.
Publicado: (2017)

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer
por: Bian, Yanlin, et al.
Publicado: (2022)

Capacity indicators for disaster preparedness in hospitals within Nairobi County, Kenya
por: Simiyu, Cynthia Nekesa, et al.
Publicado: (2014)

The Contribution of Host Cells to Pneumocystis Immunity: An Update
por: Otieno-Odhiambo, Patricia, et al.
Publicado: (2019)

Anti-PD-L1 antibody enhances curative effect of cryoablation via antibody-dependent cell-mediated cytotoxicity mediating PD-L1(high)CD11b(+) cells elimination in hepatocellular carcinoma
por: Tan, Jizhou, et al.
Publicado: (2023)

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
por: Luheshi, Nadia M., et al.
Publicado: (2016)

Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway
por: Fenwick, Craig, et al.
Publicado: (2019)

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
por: Rataj, Felicitas, et al.
Publicado: (2018)

Bacterial Community Mapping of the Mouse Gastrointestinal Tract
por: Gu, Shenghua, et al.
Publicado: (2013)

Enhanced Recovery after Surgery Protocol Accelerates Recovery of Lumbar Disc Herniation among Elderly Patients Undergoing Discectomy via Promoting Gastrointestinal Function
por: Zuo, Xiaohai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vm3g73mgg8ffnqelokn7e4tei6